| Previous Close | 0.0950 |
| Open | 0.0950 |
| Bid | 0.0800 x 0 |
| Ask | 0.0950 x 0 |
| Day's Range | 0.0800 - 0.0950 |
| 52 Week Range | 0.0650 - 0.2550 |
| Volume | 22,000 |
| Avg. Volume | 172,987 |
| Market Cap | 9.006M |
| Beta (3Y Monthly) | 2.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0230 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
The pilot formulation development and testing program to be conducted under this LOI shall focus on creation of test formulations of NeutriSci’s patented technology tablets to be modified through incorporation of TFD’s proprietary technology together with cannabinoids and other ingredients under TFD’s umbrella of products. Testing will be conducted at TFD’s facilities in Chiang Mai, Thailand.
NeutriSci International Inc. ("NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy® is pleased to announce effective May 1st, 2019 ANB Canada Inc. (“ANB”) will assume all responsibilities for retail sales and distribution of neuenergy® products in Canada. ANB not only markets, sells, warehouses and distributes consumer OTC brands, but also helps manufacturers in several areas, including generating brand awareness. ANB currently represents the brands of many manufacturers across many different product lines.
NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products. Upon the successful completion of a due-diligence period, both companies will work towards signing a definitive agreement in early Q2/2019.
SACRAMENTO, CA / ACCESSWIRE / March 25, 2019 / Neutrisci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, and Falcon Technologies, Inc. ("Falcon") (FLCN:OTC PINK) are pleased to jointly announce they have entered into a Letter of Intent to create a sublingual CBD tablet. NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products.
Neutrisci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that it has received its first order for its sublingual cannabidiol (CBD) tablets. This initial order will result in the Company reporting six figure sales for the current quarter. The quick dissolving, flavoured tablets are manufactured using the Company’s patent pending technology and offer a method to provide the consumer with a measured dose of known CBD product.
VANCOUVER, British Columbia, Dec. 06, 2018 -- NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer.